S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis.
Therapeutics targeting sphingosine-1-phosphate (S1P), a kind of lipid mediator regulating immune cell trafficking, has been emerging rapidly as a novel line of regimen for autoimmune diseases, including rheumatoid arthritis (RA). Here, we propose that S1P-targeted therapy is beneficial not only for limiting inflammation but for preventing bone-resorptive disorders, such as osteoporosis, by controlling the migratory behavior of osteoclast precursors and therefore would be good for treating elderly female RA patients who suffer from postmenopausal osteoporosis and arthritis simultaneously.
Department of Rheumatology and Clinical Research, National Osaka-Minami Medical Center, Osaka, Japan.
Junichi
J
Kikuta
Kaori
K
Iwai
Yukihiko
Y
Saeki
Masaru
M
Ishii
D000367:Age Factors; D000368:Aged; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008246:Lysophospholipids / Q000819:agonists* / Q000502:physiology; D051379:Mice; D010010:Osteoclasts / Q000187:drug effects* / Q000502:physiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000276:immunology; D049349:Receptors, Lysosphingolipid / Q000819:agonists* / Q000502:physiology; D013110:Sphingosine / Q000819:agonists / Q000031:analogs & derivatives* / Q000502:physiology; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D008246:Lysophospholipids; D049349:Receptors, Lysosphingolipid; C060506:sphingosine 1-phosphate; D013110:Sphingosine